Filtered By:
Source: American Heart Journal
Condition: Heart Attack

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 253 results found since Jan 2013.

Rationale and Design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients with Multivessel Coronary Artery Disease
Conclusion The FAME 3 study will compare in a multicenter, randomized fashion FFR-guided PCI with contemporary drug-eluting stents to CABG in patients with three-vessel coronary artery disease.
Source: American Heart Journal - July 30, 2015 Category: Cardiology Source Type: research

The relation between the presence of cardiovascular disease and major vascular risk factors in offspring and the occurrence of new vascular events in their parents already at high vascular risk
Conclusions Presence of cardiovascular disease, hypertension, hypercholesterolemia and diabetes in offspring, with diabetes mellitus being the most contributing vascular risk factor, is related to an increased risk of developing new or subsequent vascular events in patients already at high vascular risk.
Source: American Heart Journal - July 30, 2015 Category: Cardiology Source Type: research

Long-term outcomes for women vs. men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the TRILOGY ACS trial
Conclusions : Long-term ischemic and bleeding outcomes for in medically managed ACS patients were similar for women vs. men, as was treatment-related platelet reactivity. Women had a higher baseline risk profile and, after adjustment, significantly lower risk of the primary composite endpoint and all-cause death through 30 months.
Source: American Heart Journal - June 20, 2015 Category: Cardiology Source Type: research

Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel vs. clopidogrel and managed without revascularization: Insights from the TRILOGY ACS Trial
Conclusions Among ACS patients managed without revascularization, use of PPIs did not result in a differential antiplatelet response between prasugrel vs. clopidogrel but was associated with a lower incidence of MI with prasugrel. These hypothesis-generating findings suggest that factors besides platelet reactivity may underlie the differential risk of MI observed by treatment assignment with PPI use.
Source: American Heart Journal - June 11, 2015 Category: Cardiology Source Type: research

Rationale and Design of the Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial
Conclusions The IMPACT trial provides data on different management strategies for risk factor optimization in subjects following cardiovascular procedures. The results will provide a platform for the continued development of novel multidisciplinary interventions in this high-risk population.
Source: American Heart Journal - June 6, 2015 Category: Cardiology Source Type: research

Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in atrial fibrillation patients
Conclusions Urinary 11-dehydro-TxB2 levels are associated with a residual risk of CVEs and CV mortality in AF patients despite anticoagulant treatment.
Source: American Heart Journal - May 23, 2015 Category: Cardiology Source Type: research

Race and Ethnicity Influences on Cardiovascular and Renal Events in Patients with Diabetes Mellitus
Conclusion Despite similar access to care and lower CV event rates, the risk of ESRD was higher among blacks and Hispanics than whites. For blacks, but not Hispanics, this increase was independent of known attributable risk factors.
Source: American Heart Journal - May 23, 2015 Category: Cardiology Source Type: research

Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial
Conclusion In this pilot study of patients with moderate renal insufficiency undergoing cardiac catheterization, with-holding ACEI/ARB resulted in a non-significant reduction in contrast-induced AKI and a significant reduction in post-procedural rise of creatinine. This low cost intervention could be considered when referring a patient for cardiac catheterization.
Source: American Heart Journal - May 12, 2015 Category: Cardiology Source Type: research

Risk of cardiovascular events and mortality among a population-based cohort of immigrants and long-term residents with diabetes: Are all immigrants healthier and if so, for how long?
Conclusion Immigrants with diabetes are at lower risk of cardiovascular events and mortality compared to long-term residents, an effect that persists more than 10 years after arrival. Not all immigrants demonstrate this health advantage.
Source: American Heart Journal - April 22, 2015 Category: Cardiology Source Type: research

Effects of Withdrawing Versus Continuing Renin-Angiotensin Blockers on Incidence of Acute Kidney Injury in Patients with Renal Insufficiency Undergoing Cardiac Catheterization: Results from the CAPTAIN Trial
Conclusion In patients with moderate renal insufficiency undergoing cardiac catheterization, withholding ACEI/ARB reduced (without statistical significance) the incidence of contrast-induced AKI. Additionally, a lower rise in post procedural creatinine levels was also noted. This low cost intervention could be considered when referring a patient for cardiac catheterization.
Source: American Heart Journal - April 22, 2015 Category: Cardiology Source Type: research

Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Conclusions We observed consistency of effects in Asian patients receiving ticagrelor and clopidogrel in the PLATO study. The relatively modest number of Asian patients in this analysis supports further investigation of larger cohorts to confirm our observations.
Source: American Heart Journal - April 3, 2015 Category: Cardiology Source Type: research

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
Conclusion ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk.
Source: American Heart Journal - March 10, 2015 Category: Cardiology Source Type: research

A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF STUDY)
Publication date: Available online 21 February 2015 Source:American Heart Journal Author(s): Gregory Y.H. Lip , Jose Merino , Michael Ezekowitz , Kenneth Ellenbogen , Dmitry Zamoryakhin , Hans Lanz , James Jin , Naab Al-Saadi , Michele Mercuri , Andreas Goette We designed a prospective, randomized, open-label, blinded endpoint evaluation(PROBE) parallel group Phase 3b clinical trial comparing edoxaban (a new oral factor Xa inhibitor) with enoxaparin/warfarin followed by warfarin alone in subjects undergoing planned electrical cardioversion of non-valvular AF. The primary efficacy endpoint is the composite endpoints of st...
Source: American Heart Journal - February 25, 2015 Category: Cardiology Source Type: research

Rationale, design, and baseline characteristics in Elixa, a long-term cardiovascular endpoint trial of Lixisenatide versus Placebo
Conclusion ELIXA will be the first trial to report the safety and efficacy of a GLP-1RA in people with T2DM and high CV-event risk.
Source: American Heart Journal - February 13, 2015 Category: Cardiology Source Type: research

Impact of Obstructive Sleep Apnea and Continuous Positive Airway Pressure Therapy on Outcomes in Patients with Atrial Fibrillation – Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Conclusion Compared with those without, AF patients with obstructive sleep apnea have worse symptoms and higher risks of hospitalization, but similar mortality, major adverse cardiovascular outcome and AF progression rates. Clinical Trial Registration: NCT01165710 (http://www.clinicaltrials.gov)
Source: American Heart Journal - February 7, 2015 Category: Cardiology Source Type: research